Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A02985 | 34174011 | Liver Int | Ultra-processed food is associated with features of metabolic syndrome and non-alcoholic fatty liver disease. | 2021 | Details |
| A02986 | 34174003 | Hepatology | NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. | 2021 | Details |
| A02987 | 34173917 | Dig Dis Sci | Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A02988 | 34172937 | Nat Rev Gastroenterol Hepatol | Defining comprehensive models of care for NAFLD. | 2021 | Details |
| A02989 | 34172319 | Nutr Metab Cardiovasc Dis | Discovery of analogues of non-β oxidizable long-chain dicarboxylic fatty acids as dual inhibitors of fatty acids and cholesterol synthesis: Efficacy of lead compound in hyperlipidemic hamsters reveals novel mechanism. | 2021 | Details |
| A02990 | 34171957 | Vnitr Lek | The use of moxonidine in the treatment of arterial hypertension. | 2021 | Details |
| A02991 | 34171931 | Z Gastroenterol | Conventional ultrasound for diagnosis of hepatic steatosis is better than believed. | 2021 | Details |
| A02992 | 34171492 | Pharmacol Res | Hepatic stellate cells role in the course of metabolic disorders development - A molecular overview. | 2021 | Details |
| A02993 | 34171462 | Biochim Biophys Acta Gene Regul Mech | Polymorphisms rs55710213 and rs56334587 regulate SCD1 expression by modulating HNF4A binding. | 2021 | Details |
| A02994 | 34171418 | Food Chem Toxicol | Palmitoyl-CoA effect on cytochrome c release, a key process of apoptosis, from liver mitochondria of rat with sucrose diet-induced obesity. | 2021 | Details |
| A02995 | 34171397 | J Ethnopharmacol | Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway. | 2021 | Details |
| A02996 | 34171051 | Rom J Morphol Embryol | Pediatric nonalcoholic fatty liver disease - a changing diagnostic paradigm. | 2021 | Details |
| A02999 | 34169561 | J Gastroenterol Hepatol | Visceral adiposity as a risk factor for lean non-alcoholic fatty liver disease in potential living liver donors. | 2021 | Details |
| A03000 | 34169247 | JHEP Rep | Hepatic microbiome in healthy lean and obese humans. | 2021 | Details |
| A03001 | 34168615 | Front Endocrinol (Lausanne) | Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome. | 2021 | Details |
| A03002 | 34168429 | Drug Des Devel Ther | Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats. | 2021 | Details |
| A03003 | 34168408 | World J Gastroenterol | COVID-19 and pediatric fatty liver disease: Is there interplay? | 2021 | Details |
| A03004 | 34168277 | Int J Obes (Lond) | Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. | 2021 | Details |
| A03005 | 34168043 | BMJ Open Gastroenterol | Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD). | 2021 | Details |
| A03006 | 34167531 | BMC Surg | Bariatric surgery for non-alcoholic fatty liver disease in individuals with obesity (Base-NAFLD): protocol of a prospective multicenter observational follow-up study. | 2021 | Details |
| A03008 | 34165645 | J Med Ultrason (2001) | Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. | 2021 | Details |
| A03009 | 34165054 | Br J Nutr | Effect of Mediterranean diet on liver enzymes: a systematic review and meta-analysis of randomised controlled trials. | 2021 | Details |
| A03010 | 34164843 | Hepatology | On the Mechanisms of Biliary Flux. | 2021 | Details |
| A03012 | 34164507 | Ann Transl Med | Butyrate ameliorates alcoholic fatty liver disease via reducing endotoxemia and inhibiting liver gasdermin D-mediated pyroptosis. | 2021 | Details |
| A03013 | 34164242 | Cureus | Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. | 2021 | Details |
| A03014 | 34163366 | Front Pharmacol | Naringenin Attenuates Non-Alcoholic Fatty Liver Disease by Enhancing Energy Expenditure and Regulating Autophagy via AMPK. | 2021 | Details |
| A03015 | 34163108 | World J Gastroenterol | Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis. | 2021 | Details |
| A03016 | 34162924 | Sci Rep | Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation. | 2021 | Details |
| A03017 | 34162749 | Sci Transl Med | Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. | 2021 | Details |
| A03019 | 34161185 | Autophagy | Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective. | 2021 | Details |
| A03020 | 34161164 | J Med Food | Protective Role of Dietary Capsanthin in a Mouse Model of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03021 | 34160377 | Am J Gastroenterol | Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis. | 2021 | Details |
| A03022 | 34160360 | Turk J Gastroenterol | The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. | 2021 | Details |
| A03023 | 34160089 | J Gastroenterol Hepatol | Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease. | 2021 | Details |
| A03024 | 34159911 | Wiad Lek | THE EFFECT OF DOXORUBICIN-INDUCED OXIDATIVE STRESS ON CITRULLINE CONCENTRATION IN THE SMALL INTESTINAL MUCOSA AND PLASMA BLOOD IN RATS WITH NON-ALCOHOLIC STEATOHEPATITIS. | 2021 | Details |
| A03025 | 34159710 | Int J Clin Pract | Serum neuregulin 4 (NRG-4) level and non-alcoholic fatty liver disease (NAFLD): A case-control study. | 2021 | Details |
| A03026 | 34159578 | Eur J Clin Invest | The use of comics to promote health awareness: A template using nonalcoholic fatty liver disease. | 2021 | Details |
| A03027 | 34159442 | J Gastroenterol | STING and liver disease. | 2021 | Details |
| A03029 | 34159161 | Hepatobiliary Surg Nutr | Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. | 2021 | Details |
| A03030 | 34158256 | Dig Liver Dis | BRG1 regulates lipid metabolism in hepatocellular carcinoma through the PIK3AP1/PI3K/AKT pathway by mediating GLMP expression. | 2021 | Details |
| A03031 | 34157365 | Gastroenterol Hepatol | Effect of the Mediterranean diet on histological indicators and imaging tests in non-alcoholic fatty liver disease. | 2021 | Details |
| A03032 | 34156680 | Eur Rev Med Pharmacol Sci | The PKM2 activator TEPP-46 attenuates MCD feeding-induced nonalcoholic steatohepatitis by inhibiting the activation of Kupffer cells. | 2021 | Details |
| A03033 | 34156590 | Dig Dis Sci | A Decreased Response to Resistin in Mononuclear Leukocytes Contributes to Oxidative Stress in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A03034 | 34156021 | Wiad Lek | NON-ALCOHOLIC FATTY LIVER DISEASE IN THE CONTEXT OF ALTERED GUT MICROBIOTA. | 2021 | Details |
| A03035 | 34156017 | Wiad Lek | INFLUENCE OF COMPLEX TREATMENT ON BIOCHEMICAL BLOOD PARAMETERS OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND CONCOMITANT PRE-DIABETES. | 2021 | Details |
| A03036 | 34156011 | Wiad Lek | THE EFFECT OF COMPREHENSIVE TREATMENT OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH PREDIABETES ON THE LIPID PROFILE. | 2021 | Details |
| A03037 | 34155821 | Pediatr Obes | Elevated transaminases potentiate the risk for emerging dysglycemia in children with overweight and obesity. | 2021 | Details |
| A03038 | 34155801 | Liver Int | Management of NAFLD patients with advanced fibrosis. | 2021 | Details |
| A03039 | 34155799 | Liver Int | Current management of NAFLD/NASH. | 2021 | Details |
| A03040 | 34155798 | Liver Int | Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity? | 2021 | Details |
| A03041 | 34155794 | Liver Int | New drugs for NASH. | 2021 | Details |
| A03042 | 34155792 | Liver Int | Natural history of NASH. | 2021 | Details |
| A03043 | 34155789 | Liver Int | COVID-19 and the liver - Lessons learned. | 2021 | Details |
| A03045 | 34155064 | Cancer Epidemiol Biomarkers Prev | Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. | 2021 | Details |
| A03047 | 34154037 | J Gastroenterol Hepatol | Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. | 2021 | Details |
| A03048 | 34153521 | Mol Metab | Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. | 2021 | Details |
| A03052 | 34153200 | Arch Physiol Biochem | The promising roles of medicinal plants and bioactive compounds on hepatic lipid metabolism in the treatment of non-alcoholic fatty liver disease in animal models: molecular targets. | 2021 | Details |
| A03054 | 34152626 | Aliment Pharmacol Ther | Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. | 2021 | Details |
| A03055 | 34152534 | Hepatol Int | Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. | 2021 | Details |
| A03056 | 34152053 | J Sleep Res | Metabolic dysfunction in OSA: Is there something new under the sun? | 2021 | Details |
| A03057 | 34151600 | Physiol Genomics | Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. | 2021 | Details |
| A03058 | 34151243 | JHEP Rep | Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. | 2021 | Details |
| A03059 | 34149320 | GastroHep | Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know? | 2021 | Details |
| A03060 | 34149286 | Clin Exp Gastroenterol | Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease? | 2021 | Details |
| A03061 | 34147478 | Eur J Pharmacol | Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. | 2021 | Details |
| A03062 | 34147109 | BMC Endocr Disord | Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis. | 2021 | Details |
| A03063 | 34147036 | Semin Liver Dis | Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. | 2021 | Details |
| A03064 | 34146854 | Biomed Pharmacother | Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. | 2021 | Details |
| A03065 | 34146602 | Diabetes Res Clin Pract | Glycemic variability and the risk of nonalcoholic fatty liver disease : A nationwide population-based cohort study. | 2021 | Details |
| A03066 | 34145341 | Sci Rep | High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects. | 2021 | Details |
| A03067 | 34144391 | Redox Biol | Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPARγ binodal complementary modules. | 2021 | Details |
| A03069 | 34142875 | Crit Rev Food Sci Nutr | Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. | 2021 | Details |
| A03070 | 34142516 | J Pediatr Endocrinol Metab | Evaluation of clinical, endocrine and metabolic findings in obese children with and without hepatosteatosis. | 2021 | Details |
| A03071 | 34142329 | Fish Physiol Biochem | Metabolism and antioxidation regulation of total flavanones from Sedum sarmentosum Bunge against high-fat diet-induced fatty liver disease in Nile tilapia (Oreochromis niloticus). | 2021 | Details |
| A03072 | 34141987 | Hepatol Commun | A Dynamic Aspartate-to-Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. | 2021 | Details |
| A03073 | 34141981 | Hepatol Commun | Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. | 2021 | Details |
| A03074 | 34141776 | World J Clin Cases | Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic. | 2021 | Details |
| A03075 | 34141709 | Front Cell Dev Biol | New Insights Into the Role of Autophagy in Liver Surgery in the Setting of Metabolic Syndrome and Related Diseases. | 2021 | Details |
| A03076 | 34139927 | Pharm Biol | Tocopheryl quinone improves non-alcoholic steatohepatitis (NASH) associated dysmetabolism of glucose and lipids by upregulating the expression of glucagon-like peptide 1 (GLP-1) via restoring the balance of intestinal flora in rats. | 2021 | Details |
| A03077 | 34139786 | Semin Liver Dis | Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations. | 2021 | Details |
| A03078 | 34139486 | ESMO Open | Cancer and hepatic steatosis. | 2021 | Details |
| A03079 | 34139323 | Cell Mol Gastroenterol Hepatol | 6-Gingerol Ameliorates Hepatic Steatosis via HNF4α/miR-467b-3p/GPAT1 Cascade. | 2021 | Details |
| A03080 | 34139066 | Intern Med J | Towards collaborative management of nonalcoholic fatty liver disease (TCM-NAFLD): a 'real-world' pathway for fibrosis risk assessment in primary care. | 2021 | Details |
| A03081 | 34138765 | Eur J Gastroenterol Hepatol | Nonalcoholic fatty liver disease is associated with a higher incidence of coeliac disease. | 2022 | Details |
| A03082 | 34137937 | Metabolomics | Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype. | 2021 | Details |
| A03084 | 34136664 | Biochem Biophys Rep | Consumption of barley ameliorates the diabetic steatohepatitis and reduces the high transforming growth factor β expression in mice grown in α-minimum essential medium in vitro as embryos. | 2021 | Details |
| A03085 | 34136549 | Front Cardiovasc Med | The Role of Lipid Profile as an Independent Predictor of Non-alcoholic Steatosis and Steatohepatitis in Morbidly Obese Patients. | 2021 | Details |
| A03086 | 34136497 | Front Med (Lausanne) | Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. | 2021 | Details |
| A03087 | 34136174 | Food Sci Nutr | Synergistic effects of black ginseng and aged garlic extracts for the amelioration of nonalcoholic fatty liver disease (NAFLD) in mice. | 2021 | Details |
| A03088 | 34136163 | Food Sci Nutr | Effects of several tea extracts on nonalcoholic fatty liver disease in mice fed with a high-fat diet. | 2021 | Details |
| A03089 | 34135776 | Front Physiol | Cytochrome P450 Omega-Hydroxylase 4a14 Attenuates Cholestatic Liver Fibrosis. | 2021 | Details |
| A03090 | 34135558 | World J Gastroenterol | Insight into molecular mechanisms underlying hepatic dysfunction in severe COVID-19 patients using systems biology. | 2021 | Details |
| A03091 | 34135151 | Indian J Pathol Microbiol | Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease. | 2021 | Details |
| A03092 | 34134614 | BMC Genomics | Transcriptomic coordination at hepatic steatosis indicates robust immune cell engagement prior to inflammation. | 2021 | Details |
| A03093 | 34134495 | Cas Lek Cesk | Non-alcoholic fatty liver disease - how to effectively fight the nowadays most common liver disease? | 2021 | Details |
| A03095 | 34133035 | Br J Clin Pharmacol | Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. | 2021 | Details |
| A03096 | 34132935 | J Med Ultrason (2001) | Ultrasonographic grayscale findings related to fibrosis in patients with non-alcoholic fatty liver disease: comparison with transient elastography and Fib-4 index. | 2021 | Details |
| A03097 | 34132934 | J Med Ultrason (2001) | Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). | 2021 | Details |
| A03098 | 34132110 | Am J Physiol Gastrointest Liver Physiol | Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk. | 2021 | Details |
| A03099 | 34131471 | World J Hepatol | Combination of type IV collagen 7S, albumin concentrations, and platelet count predicts prognosis of non-alcoholic fatty liver disease. | 2021 | Details |